Literature DB >> 28571146

Immunohistochemical Study of MUC1, MUC2 and MUC5AC Expression in Primary Breast Carcinoma.

Daxesh Shivabhai Patel1, Siddhi Gaurish Sinai Khandeparkar2, Avinash R Joshi3, Maithili Mandar Kulkarni2, Bhagyashree Dhande1, Pranoti Lengare1, Lokesh Ashok Phegade1, Ketan Narkhede1.   

Abstract

INTRODUCTION: Breast Cancer (BC) is the second most common cancer among women in India and accounts for 7% of global burden of BC and one-fifth of all Cancers (CA) among women in India. AIM: This study was conducted for studying the expression of MUC1, MUC2 and MUC5AC in breast carcinoma.
MATERIALS AND METHODS: Fifty cases of primary breast carcinoma diagnosed between years 2013 to 2015 were included in the study. Manual tissue array technique was applied for cases subjected to Immunohistochemistry (IHC). An analysis of the expression of IHC markers (MUC1, MUC2, MUC5AC, ER, PR and HER2/neu) was attempted. Results were subjected to statistical analysis. They were considered to be significant when the p-value was less than 0.05.
RESULTS: The positivity for MUC1, MUC2 and MUC5AC in BC was 58%, 8% and 6% and for ER, PR and HER2 was 48%, 36% and 64% respectively. There was a significant correlation between MUC1 expression and ER and PR positivity. There was a significant correlation between MUC2 expression and ER positivity. No significant association was observed between MUC2 and PR expression, MUC5AC expression and ER and PR positivity. There was statistically significant correlation between negative MUC2 and MUC5AC expression and histopathological grade. It was noted that MUC2 and MUC5AC negative tumours were associated with higher tumour stage though not statistically significant. It was noted that MUC5AC negative tumours showed higher frequency of lymphovascular invasion though not statistically significant.
CONCLUSION: Our experience with the present study highlights the role of mucins in the development and progression of BC.

Entities:  

Keywords:  Immunoreactivity; Modified radical mastectomy; Mucin expression

Year:  2017        PMID: 28571146      PMCID: PMC5449792          DOI: 10.7860/JCDR/2017/26533.9707

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  14 in total

1.  EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas.

Authors:  S Luna-Moré; F Rius; B Weil; A Jimenez; M D Bautista; A Pérez-Mellado
Journal:  Pathol Res Pract       Date:  2001       Impact factor: 3.250

2.  Construction of tissue arrays without prefabricated recipient paraffin block experience of a novel technique in resource poor settings.

Authors:  Gayatri S Pathak; Sanjay D Deshmukh; Amrut V Ashturkar
Journal:  Indian J Pathol Microbiol       Date:  2011 Jul-Sep       Impact factor: 0.740

3.  Clinicoepidemiological analysis of female breast cancer patients in Kashmir.

Authors:  Shaqul Qamar Wani; Talib Khan; Saiful Y Wani; Abid H Koka; Syed Arshad; Liza Rafiq; Lone M Mqabool; Fir Afroz
Journal:  J Cancer Res Ther       Date:  2012 Jul-Sep       Impact factor: 1.805

4.  Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues.

Authors:  M B Pereira; A J Dias; C A Reis; F C Schmitt
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

5.  Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

Authors:  Emad A Rakha; Richard W G Boyce; Dalia Abd El-Rehim; Thomas Kurien; Andrew R Green; Emma C Paish; John F R Robertson; Ian O Ellis
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.

Authors:  Sean K Lau; Lawrence M Weiss; Peiguo G Chu
Journal:  Am J Clin Pathol       Date:  2004-07       Impact factor: 2.493

8.  Expression of MUC2 epithelial mucin in breast carcinoma.

Authors:  M D Walsh; M A McGuckin; P L Devine; B G Hohn; R G Wright
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

9.  Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis.

Authors:  Agnieszka Adamczyk; Joanna Niemiec; Aleksandra Ambicka; Krzysztof Małecki; Wojciech H Wysocki; Jerzy Mituś; Janusz Ryś
Journal:  Pol J Pathol       Date:  2012-12       Impact factor: 1.072

10.  Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.

Authors:  Sung-Im Do; Kyungeun Kim; Dong-Hoon Kim; Seoung Wan Chae; Yong Lai Park; Chan Heun Park; Jin Hee Sohn
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

View more
  10 in total

1.  Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.

Authors:  Anna Astashchanka; Thomas M Shroka; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2018-10-13       Impact factor: 4.872

Review 2.  Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Libin Yin; Yuyang Lin; Chenguang Li; Tao Liu; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2018-06-05       Impact factor: 2.260

3.  MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the MUC1 gene.

Authors:  Min Deng; Yiyu Qin; Xiaodong Chen; Qizhi Wang; Jianchao Wang
Journal:  Onco Targets Ther       Date:  2019-01-25       Impact factor: 4.147

Review 4.  Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Tao Liu; Libin Yin; Chenyao Li; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2019-12-20       Impact factor: 2.260

5.  Quantitative assessment of the diagnostic role of mucin family members in pancreatic cancer: a meta-analysis.

Authors:  Shunda Wang; Lei You; Menghua Dai; Yupei Zhao
Journal:  Ann Transl Med       Date:  2021-02

6.  Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer.

Authors:  Suleyman Bademler; Alisan Zirtiloglu; Murat Sari; Muhammed Zubeyr Ucuncu; Elif Bilgin Dogru; Senem Karabulut
Journal:  Biomolecules       Date:  2019-01-24

7.  Expression of Tumour-Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana.

Authors:  E Atta Manu; K Bedu-Addo; N A Titiloye; C Ameh-Mensah; F Opoku; B M Duduyemi
Journal:  J Oncol       Date:  2020-04-22       Impact factor: 4.375

8.  A Purified Aspartic Protease from Akkermansia Muciniphila Plays an Important Role in Degrading Muc2.

Authors:  Xin Meng; Wencheng Wang; Tianqi Lan; Wanxin Yang; Dahai Yu; Xuexun Fang; Hao Wu
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

9.  Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models.

Authors:  Yan Yao; Tingting Zhang; Lingyu Qi; Ruijuan Liu; Gongxi Liu; Jia Wang; Qi Song; Changgang Sun
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

10.  MUC1 and MUC5AC implication in Tunisian colorectal cancer patients

Authors:  Meriam Hazgui; Marwa Weslati; Rahma Boughriba; Donia Ounissi; Dhouha Bacha; Saadia Bouraoui
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.